Anti-SARS-CoV-2 vaccination in adolescent and adult patients with juvenile-onset systemic lupus erythematosus: tolerability and impact on disease activity
Authors' conclusion
This study confirms that anti-SARS-CoV-2 vaccination in JSLE is well tolerated
Study context
- Population
- Adolescent and adult patients with juvenile-onset SLE (JSLE) who received at least one dose of any anti-SARS-CoV-2 vaccine46 completed schedule with booster
- Participants
- 65 participants
- Outcome
- Tolerability and safety of anti-SARS-CoV-2 vaccination, including the booster
Methodological detailsmonocentric
- Monocentric
Main finding
As reported in the abstract
Mild-moderate adverse events (mainly fever, fatigue, arthromyalgias, injection-site pain)
66%
Disease flare after immunization (mainly LN)
10.8%
Observational data: associations, not effects.
Further findings
Disease activity (BILAG, SLEDAI) after vaccination
- No significant changes in BILAG and SLEDAI
Predictors of post-vaccination flare
- Flares predominantly in patients with moderate disease activity before immunization; SLEDAI ≥4 identified patients at risk of flare
- Lupus Low Disease Activity State (LLDAS) protective against post-vaccination flare
Safety
Mild-moderate adverse events
- Rate of mild-moderate adverse events (mainly fever, fatigue, arthromyalgias, injection-site pain)
- 66%
Disease flare after immunization (mainly LN)
- Flare rate
- 10.8%
Original publication
Anti-SARS-CoV-2 vaccination in adolescent and adult patients with juvenile-onset systemic lupus erythematosus: tolerability and impact on disease activity. Rheumatology (Oxford). Published 25 January 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →